Ivabradine hemisulfate | CAS# 1422274-66-5 | Biochemical

MedKoo Cat#: 576817 | Name: Ivabradine hemisulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ivabradine hemisulfate is a novel biochemical for symptomatic management of stable angina pectoris.

Chemical Structure

Ivabradine hemisulfate

CAS#1422274-66-5 (hemisulfate)

Theoretical Analysis

MedKoo Cat#: 576817

Name: Ivabradine hemisulfate

CAS#: 1422274-66-5 (hemisulfate)

Chemical Formula: C54H74N4O14S

Exact Mass: 1034.4922

Molecular Weight: 1035.26

Elemental Analysis: C, 62.65; H, 7.21; N, 5.41; O, 21.64; S, 3.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

155974-00-8 (free base) 1202000-62-1 (sulfate) 148849-67-6 (HCl) 1086026-42-7 (oxalate) 1422274-66-5 (hemisulfate)

Synonym

Ivabradine hemisulfate

IUPAC/Chemical Name

2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, sulfate (2:1)

InChi Key

AMRKLKWJQKOGOF-ITEXDBGESA-N

InChi Code

InChI=1S/2C27H36N2O5.H2O4S/c2*1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;1-5(2,3)4/h2*12-14,16,21H,6-11,15,17H2,1-5H3;(H2,1,2,3,4)/t2*21-;/m11./s1

SMILES Code

COc1cc2CCN(CCCN(C)C[C@H]3Cc4cc(OC)c(OC)cc34)C(=O)Cc2cc1OC.COc5cc6CCN(CCCN(C)C[C@H]7Cc8cc(OC)c(OC)cc78)C(=O)Cc6cc5OC.OS(=O)(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,035.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548107/ PubMed PMID: 31643437. 2: Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clin Ther. 2019 Oct;41(10):2137-2152.e12. doi: 10.1016/j.clinthera.2019.08.008. Epub 2019 Sep 21. Review. PubMed PMID: 31548105. 3: Mayhew A, Loshak H. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 15. Available from http://www.ncbi.nlm.nih.gov/books/NBK545894/ PubMed PMID: 31487130. 4: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. Review. PubMed PMID: 31400267. 5: Sattar Y, Neisani Samani E, Zafrullah F, Latchana S, Patel NB. Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives. Cureus. 2019 Apr 13;11(4):e4448. doi: 10.7759/cureus.4448. Review. PubMed PMID: 31205834; PubMed Central PMCID: PMC6561528. 6: Katsi V, Skalis G, Kallistratos MS, Tsioufis K, Makris T, Manolis AJ, Tousoulis D. Ivabradine and metoprolol in fixed dose combination: When, why and how to use it. Pharmacol Res. 2019 Aug;146:104279. doi: 10.1016/j.phrs.2019.104279. Epub 2019 May 17. Review. PubMed PMID: 31108185. 7: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. Review. PubMed PMID: 31074301. 8: Sathyamurthy I, Newale S. Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian Heart J. 2018 Dec;70 Suppl 3:S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20. Review. PubMed PMID: 30595304; PubMed Central PMCID: PMC6309574. 9: CADTH Canadian Drug Expert Committee Recommendation: Ivabradine Hydrochloride (Lancora — Servier Canada Inc.): Indication: Heart Failure, NYHA class II to III [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 24. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533855/ PubMed PMID: 30462447. 10: Pharmacoeconomic Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533848/ PubMed PMID: 30462445. 11: Patient Group Input Submissions: Ivabradine (Lancora) for Heart failure, NYHA class II to IV [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533856/ PubMed PMID: 30462443. 12: Clinical Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533838/ PubMed PMID: 30462437. 13: Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018 Jul 4;9(11):199-207. doi: 10.1177/2040622318784556. eCollection 2018 Nov. Review. PubMed PMID: 30364460; PubMed Central PMCID: PMC6196638. 14: Dodd K, Lampert BC. The Use and Indication of Ivabradine in Heart Failure. Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18. Review. PubMed PMID: 30266358. 15: Reed M, Nicolas D. Ivabradine. 2019 Oct 8. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507783/ PubMed PMID: 29939560. 16: Chow SL, Page RL 2nd, Depre C. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Rev Cardiovasc Ther. 2018 Jul;16(7):515-526. doi: 10.1080/14779072.2018.1489235. Epub 2018 Jul 2. Review. PubMed PMID: 29902387. 17: Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, Vardas P, Camici PG. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart. 2018 Mar 9;5(1):e000725. doi: 10.1136/openhrt-2017-000725. eCollection 2018. Review. PubMed PMID: 29632676; PubMed Central PMCID: PMC5888443. 18: Gee ME, Watkins AK, Brown JN, Young EJA. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Am J Cardiovasc Drugs. 2018 Jun;18(3):195-204. doi: 10.1007/s40256-017-0252-1. Review. PubMed PMID: 29330767. 19: Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018 Feb;15(2):240-247. doi: 10.1016/j.hrthm.2017.10.004. Epub 2017 Oct 7. Review. PubMed PMID: 29017929. 20: Kang S, Li CJ, Zhang XM. Ivabradine has a neutral effect on mortality in randomized controlled trials. Medicine (Baltimore). 2017 Oct;96(40):e8067. doi: 10.1097/MD.0000000000008067. Review. PubMed PMID: 28984762; PubMed Central PMCID: PMC5737998.